比较 RECIST 1.1、mRECIST 和 PERCIST 用于评估转移性神经内分泌肿瘤的肽受体放射性核素治疗反应。

Jack Zhao, Kaustav Bera, Amr Mohamed, Qiubai Li, Nikhil Ramaiya, Sree Harsha Tirumani
{"title":"比较 RECIST 1.1、mRECIST 和 PERCIST 用于评估转移性神经内分泌肿瘤的肽受体放射性核素治疗反应。","authors":"Jack Zhao, Kaustav Bera, Amr Mohamed, Qiubai Li, Nikhil Ramaiya, Sree Harsha Tirumani","doi":"10.1067/j.cpradiol.2024.10.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare RECIST 1.1, modified RECIST (mRECIST) and PERCIST for assessment of Peptide Receptor Radionuclide Therapy (PRRT) treatment response in metastatic neuroendocrine tumors.</p><p><strong>Materials: </strong>In this IRB-approved, HIPAA compliant retrospective study, patients treated with PRRT between July 2019 and Dec 2022 were identified. Inclusion criteria were presence of at least one pre-and one post-treatment imaging (CT, MRI, Ga 68 or Cu64 DOTATATE PET/CT) within one year of the start and end of PRRT respectively. The imaging was reviewed independently by two radiologists using RECIST 1.1, modified RECIST (mRECIST) and PERCIST criteria. Response of first post treatment scan and presence of disease progression during follow-up were recorded along with the date of best response and disease progression. Statistical analysis was performed to determine inter-reader agreement and agreement between the various response criteria using kappa statistics.</p><p><strong>Results: </strong>Best response by RECIST 1.1 was recorded in 26 patients (PR-7, SD- 13, PD- 6), by mRECIST in 22 patients (PR-7, SD- 10, PD- 5), by PERCIST in 14 patients (PR-4, SD- 3, PD- 7). Inter-reader agreement was highest for PERCIST (weighted kappa 0.921, standard error 0.078 95% CI 0.769 to 1.000) followed by RECIST 1.1 (weighted kappa 0.897, standard error 0.071 95% CI 0.758 to 1.000) and mRECIST (weighted kappa 0.883, standard error 0.079 95% CI 0.727 to 1.000).</p>","PeriodicalId":93969,"journal":{"name":"Current problems in diagnostic radiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of RECIST 1.1, mRECIST and PERCIST for assessment of peptide receptor radionuclide therapy treatment response in metastatic neuroendocrine tumors.\",\"authors\":\"Jack Zhao, Kaustav Bera, Amr Mohamed, Qiubai Li, Nikhil Ramaiya, Sree Harsha Tirumani\",\"doi\":\"10.1067/j.cpradiol.2024.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To compare RECIST 1.1, modified RECIST (mRECIST) and PERCIST for assessment of Peptide Receptor Radionuclide Therapy (PRRT) treatment response in metastatic neuroendocrine tumors.</p><p><strong>Materials: </strong>In this IRB-approved, HIPAA compliant retrospective study, patients treated with PRRT between July 2019 and Dec 2022 were identified. Inclusion criteria were presence of at least one pre-and one post-treatment imaging (CT, MRI, Ga 68 or Cu64 DOTATATE PET/CT) within one year of the start and end of PRRT respectively. The imaging was reviewed independently by two radiologists using RECIST 1.1, modified RECIST (mRECIST) and PERCIST criteria. Response of first post treatment scan and presence of disease progression during follow-up were recorded along with the date of best response and disease progression. Statistical analysis was performed to determine inter-reader agreement and agreement between the various response criteria using kappa statistics.</p><p><strong>Results: </strong>Best response by RECIST 1.1 was recorded in 26 patients (PR-7, SD- 13, PD- 6), by mRECIST in 22 patients (PR-7, SD- 10, PD- 5), by PERCIST in 14 patients (PR-4, SD- 3, PD- 7). Inter-reader agreement was highest for PERCIST (weighted kappa 0.921, standard error 0.078 95% CI 0.769 to 1.000) followed by RECIST 1.1 (weighted kappa 0.897, standard error 0.071 95% CI 0.758 to 1.000) and mRECIST (weighted kappa 0.883, standard error 0.079 95% CI 0.727 to 1.000).</p>\",\"PeriodicalId\":93969,\"journal\":{\"name\":\"Current problems in diagnostic radiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in diagnostic radiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1067/j.cpradiol.2024.10.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in diagnostic radiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1067/j.cpradiol.2024.10.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:比较 RECIST 1.1、改良 RECIST(mRECIST)和 PERCIST 对转移性神经内分泌肿瘤的肽受体放射性核素疗法(PRRT)治疗反应的评估:在这项经 IRB 批准、符合 HIPAA 标准的回顾性研究中,确定了 2019 年 7 月至 2022 年 12 月期间接受 PRRT 治疗的患者。纳入标准是在 PRRT 开始和结束后一年内,分别至少有一次治疗前和一次治疗后影像学检查(CT、MRI、Ga 68 或 Cu64 DOTATATE PET/CT)。影像学检查由两名放射科医生根据 RECIST 1.1、改良 RECIST (mRECIST) 和 PERCIST 标准独立完成。记录治疗后首次扫描的反应和随访期间的疾病进展情况,以及最佳反应和疾病进展的日期。采用卡帕统计法进行了统计分析,以确定阅读者之间的一致性以及各种反应标准之间的一致性:结果:26 名患者(PR-7,SD- 13,PD- 6)记录了 RECIST 1.1 最佳反应,22 名患者(PR-7,SD- 10,PD- 5)记录了 mRECIST 最佳反应,14 名患者(PR-4,SD- 3,PD- 7)记录了 PERCIST 最佳反应。PERCIST(加权卡帕0.921,标准误差0.078,95% CI 0.769-1.000)的读数间一致性最高,其次是RECIST 1.1(加权卡帕0.897,标准误差0.071,95% CI 0.758-1.000)和mRECIST(加权卡帕0.883,标准误差0.079,95% CI 0.727-1.000)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comparison of RECIST 1.1, mRECIST and PERCIST for assessment of peptide receptor radionuclide therapy treatment response in metastatic neuroendocrine tumors.

Purpose: To compare RECIST 1.1, modified RECIST (mRECIST) and PERCIST for assessment of Peptide Receptor Radionuclide Therapy (PRRT) treatment response in metastatic neuroendocrine tumors.

Materials: In this IRB-approved, HIPAA compliant retrospective study, patients treated with PRRT between July 2019 and Dec 2022 were identified. Inclusion criteria were presence of at least one pre-and one post-treatment imaging (CT, MRI, Ga 68 or Cu64 DOTATATE PET/CT) within one year of the start and end of PRRT respectively. The imaging was reviewed independently by two radiologists using RECIST 1.1, modified RECIST (mRECIST) and PERCIST criteria. Response of first post treatment scan and presence of disease progression during follow-up were recorded along with the date of best response and disease progression. Statistical analysis was performed to determine inter-reader agreement and agreement between the various response criteria using kappa statistics.

Results: Best response by RECIST 1.1 was recorded in 26 patients (PR-7, SD- 13, PD- 6), by mRECIST in 22 patients (PR-7, SD- 10, PD- 5), by PERCIST in 14 patients (PR-4, SD- 3, PD- 7). Inter-reader agreement was highest for PERCIST (weighted kappa 0.921, standard error 0.078 95% CI 0.769 to 1.000) followed by RECIST 1.1 (weighted kappa 0.897, standard error 0.071 95% CI 0.758 to 1.000) and mRECIST (weighted kappa 0.883, standard error 0.079 95% CI 0.727 to 1.000).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The "pseudo-pulmonary AVM sign": an aid to the diagnosis of histoplasmosis and differentiation from pulmonary arteriovenous malformations. A stroke imaging protocol in patients with a history of contrast-induced anaphylaxis. Large language models as an academic resource for radiologists stepping into artificial intelligence research. Assessing radiologist performance. Tumor mutational burden as a marker for radiologic response to immune checkpoint inhibitors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1